Primary Care/Hospitalist
RSSArticles
-
Options might begin to emerge with new data out on LARC
The American College of Obstetricians and Gynecologists says that long-acting reversible contraception (LARC) methods are safe, effective, and appropriate options for teens, but some might perceive high discontinuation rates among younger women and therefore steer patients away from them. -
Contraceptive Technology Update - March 2014 Issue in PDF
-
Interpregnancy interval — You can help women
New research indicates that provision of effective contraception at the time of postpartum follow-up is a key strategy for achieving optimal interpregnancy intervals. -
STI Quarterly: What is the role of express STI testing?
Declining resources in the face of increasing demand are causing sexually transmitted infection (STI) clinics to review new strategies to maximize efficiency without compromising quality of care. -
Clinicians missing mark on sex talk with teens
In a study looking at discussions held between pediatricians and family medicine physicians and teen-age patients, results show less than two-thirds of such interactions included talk about sex, sexuality, or dating during annual visits. -
Scope outbreak raises troubling questions
An upper endoscopy procedure performed on some half million patients annually in the United States might pose risk for transmission of the emerging New Delhi variety of carbapenem-resistant Enterobacteriaceae (CRE), even if current cleaning and high level disinfection protocols are followed. -
How to address deaths from ovarian cancer
A woman in her late 40s dies less than a year after ovarian cancer is diagnosed. She has three daughters ranging from 15 to 25 years of age. How can ovarian cancer be prevented in these three young women? How can ovarian cancer be prevented during the lifetime of ANY woman, whether or not she has a family history of ovarian cancer?
-
Multipurpose methods show research advances
Strides are being made in development of multipurpose prevention technologies, defined as a single product or strategy configured for at least two sexual and reproductive health prevention indications: unintended pregnancy, HIV, and other sexually transmitted infections. -
Contraceptive Technology Update - February 2014 Issue in PDF
-
FDA eyes LNG ECP label change in light of research on weight impact
Labeling for the European levonorgestrel (LNG) emergency contraceptive pill NorLevo has been revised due to data indicating lower drug efficacy in women weighing 165 pounds and above. This move has led U.S. regulators to assess data on similar products.